Antithrombotic Medication for Cardioembolic Stroke Prevention
Embolism of cardiac origin accounts for about 20% of ischemic strokes. Nonvalvular atrial fibrillation is the most frequent cause of cardioembolic stroke. Approximately 1% of population is affected by atrial fibrillation, and its prevalence is growing with ageing in the modern world. Strokes due to...
Saved in:
Main Authors: | M. Àngels Font, Jerzy Krupinski, Adrià Arboix |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2011-01-01
|
Series: | Stroke Research and Treatment |
Online Access: | http://dx.doi.org/10.4061/2011/607852 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The influence of COVID-19 pandemic on secondary prevention in non-COVID patients with cardioembolic stroke
by: Lučić-Prokin Aleksandra L., et al.
Published: (2024-01-01) -
A Bioclinical Pattern for the Early Diagnosis of Cardioembolic Stroke
by: Bruno Zecca, et al.
Published: (2014-01-01) -
Cardioembolic but Not Other Stroke Subtypes Predict Mortality Independent of Stroke Severity at Presentation
by: Latha Ganti Stead, et al.
Published: (2011-01-01) -
Risk Factors Associated with Cardioembolic Stroke in Patients with non Valvular Atrial Fibrillation
by: Daniel Guerra García, et al.
Published: (2018-02-01) -
Antithrombotic Therapy Duration after Patent Foramen Ovale Closure for Stroke Prevention: Impact on Long-Term Outcome
by: Joelle Kefer, et al.
Published: (2022-01-01)